U.S. missile defense system during U.S.-Israeli military exercise. Photo: Jack Guez/AFP/Getty Images

The U.S. has increased its missile use in recent years, and the weaknesses in the industrial base may hurt its ability to support that level of munition use going forward.

Why it matters: America faces national security threats around the world from countries like Iran, Russia, and North Korea, and the Pentagon's FY2017 Annual Industrial Capabilities Report paints a somewhat bleak picture of U.S. munition capabilities, identifying "critical components within the missile sector industrial base...at risk." Defense News' Aaron Mehta identifies the vulnerabilities as lack of "diversity," and "knowledge on how to develop new systems."

The report attributed vulnerabilities to "surge requirements" of the industry during times of conflict. Andrew Hunter, director of the Center for Strategic and International Studies' Defense-Industrial Initiatives Group, told Axios we "can and should be doing a better job at keeping industry at more of a steady pace."

"We really did a number on the defense industry in the last decade. ... If we got into a major conflict, we'd be behind the power curve with the supply chain."
— Andrew Hunter to Axios

The areas of highest risk, per the Pentagon's report:

  • Solid Rocket Motors: One of the two domestic suppliers of SRMs set to take over the majority of production. This could raise costs, decrease research and development efforts, and hurt security of supply, per the report.
  • Thermal Batteries: One company is making the vast majority of thermal batteries, which are used in all missiles and precision-guided munitions. The dependency on this one supplier puts the industry at risk and has hurt "[i]nvestments in improvements" to technologies.
  • Fuzes: An excess capacity of fuzes — used on all missile programs and munitions —  limits competition and improvements to the technology.
  • Small Turbine Engines: There will soon be only one supplier of small turbine engines — Williams International — as the other "cannot sustain themselves any longer."

Go deeper

Updated 2 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Global: Total confirmed cases as of 9 p.m. ET: 20,755,406 — Total deaths: 752,225— Total recoveries: 12,917,934Map.
  2. U.S.: Total confirmed cases as of 9 p.m. ET: 5,246,760 — Total deaths: 167,052 — Total recoveries: 1,774,648 — Total tests: 64,831,306Map.
  3. Politics: House Democrats to investigate scientist leading "Operation Warp Speed" vaccine projectMcConnell announces Senate will not hold votes until Sept. 8 unless stimulus deal is reached.
  4. 2020: Biden calls for 3-month national mask mandateBiden and Harris to receive coronavirus briefings 4 times a week.
  5. States: Georgia Gov. Brian Kemp to drop lawsuit over Atlanta's mask mandate.
  6. Business: Why the CARES Act makes 2020 the best year for companies to lose money.
  7. Public health: Fauci's guidance on pre-vaccine coronavirus treatments Cases are falling, but don't get too comfortable.

Trump says he intends to give RNC speech on White House lawn

President Trump speaking to reporters on South Lawn in July. Photo: Jabin Botsford/The Washington Post via Getty Images

President Trump told the New York Post on Thursday that he plans to deliver his Republican National Convention speech from the White House lawn, despite bipartisan criticism of the optics and legality of the location.

Why it matters: Previous presidents avoided blurring staged campaign-style events — like party conventions — with official business of governing on the White House premises, per Politico.

Fauci's guidance on pre-vaccine coronavirus treatments

Illustration: Aïda Amer/Axios

Antibody drugs and various medicine cocktails against the coronavirus are progressing and may provide some relief before vaccines.

The big picture: Everyone wants to know how and when they can return to "normal" life, as vaccines are not expected to be ready for most Americans for at least a year. Two therapies are known to be helpful, and more could be announced by late September, NIAID Director Anthony Fauci tells Axios.